Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.

Akiyama Y, Komiyama M, Nakamura Y, Iizuka A, Oshita C, Kume A, Nogami M, Miyata H, Ashizawa T, Yoshikawa S, Kiyohara Y, Yamaguchi K.

Cancer Immunol Immunother. 2012 Dec;61(12):2311-9. doi: 10.1007/s00262-012-1298-1. Epub 2012 Jun 16.

PMID:
22707303
2.
3.

Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.

Akiyama Y, Maruyama K, Tai S, Komiyama M, Iizuka A, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.

Anticancer Res. 2009 Feb;29(2):647-55.

4.

Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.

Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K.

J Immunol. 2002 Jul 1;169(1):575-80.

5.

A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.

Oiso M, Eura M, Katsura F, Takiguchi M, Sobao Y, Masuyama K, Nakashima M, Itoh K, Ishikawa T.

Int J Cancer. 1999 May 5;81(3):387-94.

6.
7.

Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.

Hao X, Shao Y, Ren X, Liu H, Xu Q, Li H, Zhang P, An X, Ren B.

J Cancer Res Clin Oncol. 2002 Sep;128(9):507-15. Epub 2002 Aug 21.

PMID:
12242516
8.

Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.

Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T.

Clin Cancer Res. 1999 Aug;5(8):2236-41.

9.

Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.

Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P.

J Immunol. 1999 Sep 1;163(5):2928-36.

10.

Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.

Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Yamaguchi K.

Anticancer Res. 2004 Mar-Apr;24(2B):571-7.

12.

Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen.

Tiriveedhi V, Sarma NJ, Subramanian V, Fleming TP, Gillanders WE, Mohanakumar T.

Hum Immunol. 2012 Jan;73(1):11-6. doi: 10.1016/j.humimm.2011.10.017. Epub 2011 Oct 23.

13.

Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.

So T, Hanagiri T, Chapiro J, Colau D, Brasseur F, Yasumoto K, Boon T, Coulie PG.

Cancer Immunol Immunother. 2007 Feb;56(2):259-69. Epub 2006 Jun 7.

PMID:
16758204
14.

Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.

Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E, Ishikawa T.

Jpn J Clin Oncol. 2000 Mar;30(3):117-21.

15.

Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.

Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M.

Clin Cancer Res. 2002 Dec;8(12):3885-92.

16.

Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.

Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.

Cancer Res. 1997 Feb 15;57(4):735-41.

17.
18.

Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells.

Jia ZC, Tian Y, Huang ZM, Wang JX, Fu XL, Ni B, Wu YZ.

Cancer Biol Ther. 2011 Feb 15;11(4):395-400. Epub 2011 Feb 15.

PMID:
21124073
19.

Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.

Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M.

Clin Cancer Res. 2001 Jan;7(1):23-31.

20.

Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.

Mimura K, Kono K, Southwood S, Fikes J, Takahashi A, Miyagawa N, Sugai H, Fujii H.

Cancer Immunol Immunother. 2006 Nov;55(11):1358-66. Epub 2006 Jan 25.

PMID:
16435129
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk